CADScor®System: Overview

An advanced acoustic-based diagnostic aid to easily and quickly rule out significant coronary artery disease at point of care.*

Book a CADScor®System demo
Use CADScor®System to Determine if Chest Pain is Related to the Heart*

CADScor®System is a point-of-care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. The system calculates a patient-specific CAD-score, and couples it with risk factors to rapidly indicate the patient’s risk of significant coronary stenosis for immediate risk stratification, prior to potential secondary evaluation.2 CADScor®System has been used in over 29,000 patient assessments 3 and has CE-marking and FDA De Novo clearance.

How it works

CADScor®System Uses Ultra-Sensitive Acoustics and AI to Rapidly Rule-Out Significant Coronary Artery Disease in 10 Minutes¹*

Non-invasive and radiation-free assessment for early rule-out of significant CAD.

Can help save costs of more advanced CAD diagnostics in up to 35% of patients.²

Rapid and easy-to-use, with clear results in 10 minutes.

An Individual CAD-score Indicates Low or Elevated Significant CAD Risk in Patients

The CAD-score is based on a phonocardiographic assessment, AI-powered calculations and risk factors.¹

Low Risk

Significant CAD rule-out in 35% of patients². Seek alternative diagnosis for symptoms.

Elevated Risk

Significant CAD cannot be ruled out. Refer for further diagnostics.

CADScor®System Research, Development and Clinical Studies

CADScor®System is approved in Europe with CE-marking and has received FDA De Novo clearance as a diagnostic aid for symptomatic patients with suspected CAD. Multiple clinical studies have been published to demonstrate CADScor®System’s performance.

View research
Physicians’ Experiences Using CADScor®System
Explore customer feedback

Schedule a demo of the CADScor®System

Schedule a free demo of CADScor®System and learn how you can rule out significant CAD patients in 10 minutes.*

By submitting your information, you confirm you would like to be contacted by Acarix. Read our privacy notice here, if you want to know more about how we treat and protect your personal data.

  1. Winther S, et al. Heart 2018;104:928–935 (Dan-NICAD I)
  2. User manual US-FDA v.12.Y, prevalence 10,7%
  3. Based on commercial patch use since 2017
*Rule-out with at least 96% confidence (NPV)

Important Safety Information